Literature DB >> 25614117

Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.

Zhipei Sang1, Yan Li1, Xiaoming Qiang1, Ganyuan Xiao1, Qiang Liu1, Zhenghuai Tan2, Yong Deng3.   

Abstract

To discover multifunctional agents for the treatment of Alzheimer's disease (AD), a series of scutellarein carbamate derivatives were designed and synthesized based on the multitarget-directed ligand strategy. Their acetylcholinesterase and butyrylcholinesterase inhibitory activities, antioxidant activities, metal-chelating properties and neuroprotective effects against hydrogen peroxide induced PC12 cell injury were evaluated in vitro. The results showed that most of the synthetic compounds exhibited good multifunctional activities. In particular, compound 15c exhibited dual inhibitory potency on acetylcholinesterase and butyrylcholinesterase with IC50 values of 0.57 and 22.6μM, respectively, and good antioxidative activity, with a value 1.3-fold of Trolox. In addition, 15c acted as a selective biometal chelator and possessed neuroprotective effects. Furthermore, 15c could cross the blood-brain barrier (BBB) in vitro and had significant neuroprotective effects in scopolamine-induced cognitive impairment in mice. Taken together, these results suggest that compound 15c might be a potential multifunctional agent for the treatment of AD.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Antioxidant activity; Cholinesterase inhibitors; Metal-chelating agents; Neuroprotective effects; Scutellarein carbamate derivatives

Mesh:

Substances:

Year:  2015        PMID: 25614117     DOI: 10.1016/j.bmc.2015.01.005

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  12 in total

1.  Scutellarin suppresses neuroinflammation via the inhibition of the AKT/NF-κB and p38/JNK pathway in LPS-induced BV-2 microglial cells.

Authors:  Pengtao You; San Fu; Kun Yu; Yu Xia; Hezhen Wu; Yanfang Yang; Chaozhi Ma; Dan Liu; Xin Chen; Jun Wang; Xiaochuan Ye; Yanwen Liu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-04-21       Impact factor: 3.000

Review 2.  Hybrids: a new paradigm to treat Alzheimer's disease.

Authors:  Manjinder Singh; Maninder Kaur; Navriti Chadha; Om Silakari
Journal:  Mol Divers       Date:  2015-09-02       Impact factor: 2.943

3.  Chromone-lipoic acid conjugate: Neuroprotective agent having acceptable butyrylcholinesterase inhibition, antioxidant and copper-chelation activities.

Authors:  Leili Jalili-Baleh; Hamid Nadri; Hamid Forootanfar; Tuba Tüylü Küçükkılınç; Beyza Ayazgök; Mohammad Sharifzadeh; Mahban Rahimifard; Maryam Baeeri; Mohammad Abdollahi; Alireza Foroumadi; Mehdi Khoobi
Journal:  Daru       Date:  2021-01-09       Impact factor: 3.117

Review 4.  Advances in Multi-Functional Ligands and the Need for Metal-Related Pharmacology for the Management of Alzheimer Disease.

Authors:  Abha Sharma; Vidhu Pachauri; S J S Flora
Journal:  Front Pharmacol       Date:  2018-11-15       Impact factor: 5.810

5.  Novel Tacrine-Scutellarin Hybrids as Multipotent Anti-Alzheimer's Agents: Design, Synthesis and Biological Evaluation.

Authors:  Katarina Spilovska; Jan Korabecny; Vendula Sepsova; Daniel Jun; Martina Hrabinova; Petr Jost; Lubica Muckova; Ondrej Soukup; Jana Janockova; Tomas Kucera; Rafael Dolezal; Eva Mezeiova; Daniel Kaping; Kamil Kuca
Journal:  Molecules       Date:  2017-06-16       Impact factor: 4.411

6.  A One-Pot Three-Component Synthesis and Investigation of the In Vitro Mechanistic Anticancer Activity of Highly Functionalized Spirooxindole-Pyrrolidine Heterocyclic Hybrids.

Authors:  Raju Suresh Kumar; Dhaifallah M Al-Thamili; Abdulrahman I Almansour; Natarajan Arumugam; Faruq Mohammad
Journal:  Molecules       Date:  2020-11-27       Impact factor: 4.411

7.  On the Scavenging Ability of Scutellarein against the OOH Radical in Water and Lipid-like Environments: A Theoretical Study.

Authors:  Maciej Spiegel; Tiziana Marino; Mario Prejanò; Nino Russo
Journal:  Antioxidants (Basel)       Date:  2022-01-25

Review 8.  Erigeron breviscapus (Vant.) Hand-Mazz.: A Promising Natural Neuroprotective Agent for Alzheimer's Disease.

Authors:  Xiaoyu Dong; Shengtao Qu
Journal:  Front Pharmacol       Date:  2022-04-26       Impact factor: 5.988

Review 9.  Heterocyclic compounds as key structures for the interaction with old and new targets in Alzheimer's disease therapy.

Authors:  Asha Hiremathad; Luca Piemontese
Journal:  Neural Regen Res       Date:  2017-08       Impact factor: 5.135

10.  Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors.

Authors:  Maja Przybyłowska; Krystyna Dzierzbicka; Szymon Kowalski; Klaudia Chmielewska; Iwona Inkielewicz-Stepniak
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.